JW Pharmaceutical Corporation 001060
KRX · South Korea · Health Technology
KRW 26,850.00-300.00 (-1.10%)
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SEOUL, South Korea, August 13, 2026--JW Pharmaceutical proved the efficacy and safety of its gout drug candidate "Epaminurad" in a Phase 3 clinical trial.
SEOUL, South Korea, June 11, 2026--JW Pharmaceutical highlighted the therapeutic potential of DDC-02 in multiple neurodevelopmental disorder models at WODC USA 2026
Gan & Lee will receive a $5m upfront payment plus up to $76.1m in milestone payments.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.